These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36942414)

  • 1. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
    Yin X; He L; Guo Z
    Immunology; 2023 Aug; 169(4):400-411. PubMed ID: 36942414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.
    Lamarche C; Ward-Hartstonge K; Mi T; Lin DTS; Huang Q; Brown A; Edwards K; Novakovsky GE; Qi CN; Kobor MS; Zebley CC; Weber EW; Mackall CL; Levings MK
    Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2219086120. PubMed ID: 36972454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of single-cell omics for chimeric antigen receptor T cell therapy.
    Ghaffari S; Saleh M; Akbari B; Ramezani F; Mirzaei HR
    Immunology; 2024 Mar; 171(3):339-364. PubMed ID: 38009707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
    Mao R; Hussein MS; He Y
    Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional rewiring in CD8
    Srinivasan S; Armitage J; Nilsson J; Waithman J
    Front Immunol; 2024; 15():1412731. PubMed ID: 39399500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Choi BD; Maus MV; June CH; Sampson JH
    Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exhaustion of CAR T cells: potential causes and solutions.
    Kouro T; Himuro H; Sasada T
    J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
    Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
    J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering chimeric antigen receptor T cells for solid tumour therapy.
    Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y
    Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
    Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
    Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.
    Ahn T; Bae EA; Seo H
    Mol Ther; 2024 Jun; 32(6):1617-1627. PubMed ID: 38582965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
    Kagoya Y
    Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
    Abbott RC; Cross RS; Jenkins MR
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.